ACE inhibitors in non-ischaemic heart failure: Results from the MEGA trials

Jay N Cohn

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Large-scale trials have demonstrated a consistent mortality reduction from angiotensin converting enzyme (ACE) inhibitor therapy for chronic heart failure. Nonetheless, the pharmacologic and physiologic mechanisms of this favourable affect and the appropriate target population remain controversial. ACE inhibitors exert vasodilator, neurohormonal inhibiting and growth inhibiting effects that may contribute to the clinical response. They improve pump function and prevent ventricular remodelling, but they also may exert an antiarrhythmic effect. They may prevent coronary ischaemic events but appear to reduce cardiovascular event rates even more in non-ischaemic than in ischaemic heart diseases. Their efficacy in early stages of asymptomatic heart disease and the optimal dose of the drugs for long-term benefit require further study.

Original languageEnglish (US)
Pages (from-to)133-136
Number of pages4
JournalEuropean Heart Journal
Volume16
Issue numberSUPPL. O
StatePublished - Dec 1 1995

Keywords

  • Angiotensin
  • Arrhythmias
  • Pump failure
  • Remodelling
  • Vasodilation

Fingerprint Dive into the research topics of 'ACE inhibitors in non-ischaemic heart failure: Results from the MEGA trials'. Together they form a unique fingerprint.

Cite this